Compare AMPG & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMPG | ANL |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.1M | 62.0M |
| IPO Year | N/A | 2023 |
| Metric | AMPG | ANL |
|---|---|---|
| Price | $4.02 | $2.01 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 655.8K | ★ 1.3M |
| Earning Date | 11-14-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,571,945.00 | N/A |
| Revenue This Year | $168.18 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 93.47 | N/A |
| 52 Week Low | $1.21 | $0.88 |
| 52 Week High | $4.89 | $2.75 |
| Indicator | AMPG | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 64.51 | 69.41 |
| Support Level | $3.36 | $1.63 |
| Resistance Level | $3.90 | $1.93 |
| Average True Range (ATR) | 0.35 | 0.15 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 85.22 | 93.16 |
AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.